Tralokinumab,一种抗il -13单抗,用于治疗哮喘和COPD。

Garry M Walsh
{"title":"Tralokinumab,一种抗il -13单抗,用于治疗哮喘和COPD。","authors":"Garry M Walsh","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and COPD. There is compelling evidence that IL-13 is a key mediator in the inflammatory processes in the asthmatic lung. Tralokinumab (CAT-354), under development by MedImmune, is an injectable, anti-IL-13 humanized mAb for the potential treatment of asthma and COPD. In a study in mice, tralokinumab prevented the development of the asthmatic phenotype, including eosinophil recruitment and airway hyperresponsiveness. In clinical trials, tralokinumab demonstrated favorable safety and pharmacokinetic profiles, both in healthy volunteers and in patients with asthma. This review summarizes the problems and successes regarding recent developments in mAb-based strategies targeted against IL-13 in asthma and COPD, with an emphasis on tralokinumab.</p>","PeriodicalId":10978,"journal":{"name":"Current opinion in investigational drugs","volume":"11 11","pages":"1305-12"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.\",\"authors\":\"Garry M Walsh\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and COPD. There is compelling evidence that IL-13 is a key mediator in the inflammatory processes in the asthmatic lung. Tralokinumab (CAT-354), under development by MedImmune, is an injectable, anti-IL-13 humanized mAb for the potential treatment of asthma and COPD. In a study in mice, tralokinumab prevented the development of the asthmatic phenotype, including eosinophil recruitment and airway hyperresponsiveness. In clinical trials, tralokinumab demonstrated favorable safety and pharmacokinetic profiles, both in healthy volunteers and in patients with asthma. This review summarizes the problems and successes regarding recent developments in mAb-based strategies targeted against IL-13 in asthma and COPD, with an emphasis on tralokinumab.</p>\",\"PeriodicalId\":10978,\"journal\":{\"name\":\"Current opinion in investigational drugs\",\"volume\":\"11 11\",\"pages\":\"1305-12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in investigational drugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in investigational drugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

生物制药方法已被用于靶向控制哮喘和COPD气道炎症过程中的关键因素。有令人信服的证据表明,IL-13是哮喘肺炎症过程中的关键介质。Tralokinumab (CAT-354)由MedImmune公司开发,是一种可注射的抗il -13人源化单抗,有望治疗哮喘和COPD。在一项小鼠研究中,曲洛单抗阻止了哮喘表型的发展,包括嗜酸性粒细胞募集和气道高反应性。在临床试验中,曲洛单抗在健康志愿者和哮喘患者中均表现出良好的安全性和药代动力学特征。这篇综述总结了针对IL-13在哮喘和慢性阻塞性肺病中基于单抗的策略的最新进展的问题和成功,重点是曲罗单抗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Biopharmaceutical approaches have been used to target key elements in the processes controlling airway inflammation in asthma and COPD. There is compelling evidence that IL-13 is a key mediator in the inflammatory processes in the asthmatic lung. Tralokinumab (CAT-354), under development by MedImmune, is an injectable, anti-IL-13 humanized mAb for the potential treatment of asthma and COPD. In a study in mice, tralokinumab prevented the development of the asthmatic phenotype, including eosinophil recruitment and airway hyperresponsiveness. In clinical trials, tralokinumab demonstrated favorable safety and pharmacokinetic profiles, both in healthy volunteers and in patients with asthma. This review summarizes the problems and successes regarding recent developments in mAb-based strategies targeted against IL-13 in asthma and COPD, with an emphasis on tralokinumab.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信